Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Frontier Novelties of Nanotechnology in Cancer Targeting
share announcement

Frontier Novelties of Nanotechnology in Cancer Targeting

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 January 2022) | Viewed by 11546

Special Issue Editors

Prof. Dr. Jin-Seok Kim

E-Mail Website
Guest Editor
College of Pharmacy, Sookmyung Women’s University, Seoul 04310, Republic of Korea
Interests: nanomedicine; liposome; drug targeting; formulation; DDS
Prof. Dr. Dae Hwan Shin

E-Mail Website
Guest Editor
College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea
Interests: drug delivery system; nanoparticle; pharmacokinetics; thermogel; cancer therapy; organ-on-a-chip

Special Issue Information

Dear colleagues,

A better understanding of drug delivery systems is essential for the development of chemotherapy. In particular, interest in drug delivery systems using nanoscale particles is increasing. Advanced nanoparticles such as micelles and liposomes are expected to play a more important role not only in cancer inhibition but also in preventing cancer recurrence. Because each cancer has different characteristics, the shape and size of the nanoparticle transfer system must be tailored to a specific tumor. To treat tumors most effectively, unlike previous models that simplified nanoparticle morphology, drug designers need models that can accurately predict the optimal particle shapes and sizes. The Special Issue "Frontier Novelties of Nanotechnology in Cancer Targeting" will feature a variety of topics related to cancer therapy using advanced nanoparticles.

Prof. Dr. Jin-Seok Kim
Prof. Dr. Dae Hwan Shin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • advanced nanotechnology
  • micelles
  • liposomes
  • tumor targeting
  • cancer therapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 6831 KiB  
Article
The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models
by Dezhi Sui, Xianmin Meng, Changzhi Li, Xueying Tang, Ying Qin, Ning Zhang, Junqiang Ding, Xinrong Liu, Yihui Deng and Yanzhi Song
Pharmaceutics 2022, 14(3), 545; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14030545 - 28 Feb 2022
Cited by 8 | Viewed by 2113
Abstract
In preclinical studies of young mice, nanoparticles showed excellent anti-tumor therapeutic effects by harnessing Peripheral Blood Monocytes (PBMs) and evading the immune system. However, the changes of age will inevitably affect PBMs and the immune system, and there is a serious lack of [...] Read more.
In preclinical studies of young mice, nanoparticles showed excellent anti-tumor therapeutic effects by harnessing Peripheral Blood Monocytes (PBMs) and evading the immune system. However, the changes of age will inevitably affect PBMs and the immune system, and there is a serious lack of relevant research. Sialic acid (SA)-octadecylamine (ODA) was synthesized, and SA- or polyethylene glycol (PEG)-modified epirubicin (EPI) liposomes (EPI-SL and EPI-PL, respectively) were prepared to explore differences in antitumor treatment using 8-month-old and 8-week-old Kunming mice. Based on presented data, 8-month-old mice had more PBMs in peripheral blood than 8-week-old mice, and age differences resulted in different anti-tumor treatment effects following EPI-SL and EPI-PL treatment. Following EPI-PL administration, the tumor volume was significantly smaller in 8-week-old mice than in 8-month-old mice (* p < 0.05). Eight-month-old mice treated with EPI-SL (8M-SL) presented no damage to healthy tissue, with a 100% survival rate, and 50% mice in 8M-SL showed ‘shedding’ of tumor tissues from the growth site. Accordingly, 8-month-old mice treated with EPI-SL achieved the best therapeutic effect at different ages and with different liposomes. EPI-SL could improve the antitumor effect of 8-week-old and 8-month-old mice. Full article
(This article belongs to the Special Issue Frontier Novelties of Nanotechnology in Cancer Targeting)
►▼ Show Figures

Graphical abstract

14 pages, 4929 KiB  
Article
In Vivo Biodistribution, Clearance, and Biocompatibility of Multiple Carbon Dots Containing Nanoparticles for Biomedical Application
by Jinfeng Liao, Yuan Yao, Cheng-Hao Lee, Yongzhi Wu and Pei Li
Pharmaceutics 2021, 13(11), 1872; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13111872 - 05 Nov 2021
Cited by 10 | Viewed by 2076
Abstract
Current research on the use of carbon dots for various biological systems mainly focuses on the single carbon dots, while particles that contain multiple carbon dots have scarcely been investigated. Here, we assessed multiple carbon dots-crosslinked polyethyleneimine nanoparticles (CDs@PEI) for their in vivo [...] Read more.
Current research on the use of carbon dots for various biological systems mainly focuses on the single carbon dots, while particles that contain multiple carbon dots have scarcely been investigated. Here, we assessed multiple carbon dots-crosslinked polyethyleneimine nanoparticles (CDs@PEI) for their in vivo biodistribution, clearance, biocompatibility, and cellular uptake. The in vivo studies demonstrate three unique features of the CDs@PEI nanoparticles: (1) the nanoparticles possess tumor-targeting ability with steady and prolonged retention time in the tumor region. (2) The nanoparticles show hepatobiliary excretion and are clear from the intestine in feces. (3) The nanoparticles have much better biocompatibility than the polyethyleneimine passivated single carbon dots (PEI-CD). We also found that pegylated CDs@PEI nanoparticles can be effectively taken up by the cells, which the confocal laser scanning microscope can image under different excitation wavelengths (at 405, 488, and 800 nm). These prior studies provide invaluable information and new opportunities for this new type of intrinsic photoluminescence nanoparticles in carbon dot-based biomedical applications. Full article
(This article belongs to the Special Issue Frontier Novelties of Nanotechnology in Cancer Targeting)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 3170 KiB  
Review
Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy
by Xiaoqiu Xu, Tong Li and Ke Jin
Pharmaceutics 2022, 14(5), 1109; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14051109 - 23 May 2022
Cited by 14 | Viewed by 3014
Abstract
Undesirable side effects and multidrug resistance are the major obstacles in conventional chemotherapy towards cancers. Nanomedicines provide alternative strategies for tumor-targeted therapy due to their inherent properties, such as nanoscale size and tunable surface features. However, the applications of nanomedicines are hampered in [...] Read more.
Undesirable side effects and multidrug resistance are the major obstacles in conventional chemotherapy towards cancers. Nanomedicines provide alternative strategies for tumor-targeted therapy due to their inherent properties, such as nanoscale size and tunable surface features. However, the applications of nanomedicines are hampered in vivo due to intrinsic disadvantages, such as poor abilities to cross biological barriers and unexpected off-target effects. Fortunately, biomimetic nanomedicines are emerging as promising therapeutics to maximize anti-tumor efficacy with minimal adverse effects due to their good biocompatibility and high accumulation abilities. These bioengineered agents incorporate both the physicochemical properties of diverse functional materials and the advantages of biological materials to achieve desired purposes, such as prolonged circulation time, specific targeting of tumor cells, and immune modulation. Among biological materials, mammalian cells (such as red blood cells, macrophages, monocytes, and neutrophils) and pathogens (such as viruses, bacteria, and fungi) are the functional components most often used to confer synthetic nanoparticles with the complex functionalities necessary for effective nano-biointeractions. In this review, we focus on recent advances in the development of bioinspired and biomimetic nanomedicines (such as mammalian cell-based drug delivery systems and pathogen-based nanoparticles) for targeted cancer therapy. We also discuss the biological influences and limitations of synthetic materials on the therapeutic effects and targeted efficacies of various nanomedicines. Full article
(This article belongs to the Special Issue Frontier Novelties of Nanotechnology in Cancer Targeting)
►▼ Show Figures

Figure 1

32 pages, 5193 KiB  
Review
Targeting Engineered Nanoparticles for Breast Cancer Therapy
by Kumar Ganesan, Yan Wang, Fei Gao, Qingqing Liu, Chen Zhang, Peng Li, Jinming Zhang and Jianping Chen
Pharmaceutics 2021, 13(11), 1829; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13111829 - 01 Nov 2021
Cited by 33 | Viewed by 3698
Abstract
Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC [...] Read more.
Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC. Full article
(This article belongs to the Special Issue Frontier Novelties of Nanotechnology in Cancer Targeting)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop